-
Item new peer-reviewed
An oral KRAS G12D inhibitor shrank tumours in a third of treated pancreatic cancers
In a phase 1 trial of 74 heavily pretreated patients with KRAS G12D-mutant advanced solid tumours, the oral inhibitor GFH375 produced confirmed responses in 35.1% of pancreatic cancers and 35.7% of non-small cell lung cancers, with median overall survival of 9.9 and 13.4 months respectively.
